Skip to main content

Hanjing Peng, PhD

Hanjing Peng, PhD

Project title
"Targeting the proteasome using a hybrid, combinatorial rapafucin library"

Dr. Peng seeks to identify compounds that inhibit the proteasome, the protein degradation machinery in the cell that maintains the balance of cell growth and death. Inhibitors that regulate proteasome function are potential anticancer drugs. Inspired by the functional mechanism of a class of natural products that includes FK506 and rapamycin, she has designed and constructed a synthetic library of compounds (macrocyclic "rapafucin") in search of potent proteasome inhibitors. She hopes to discover new anticancer drug candidates with lower toxicity or side effects than current drugs. 

Institution
The Johns Hopkins University
Sponsor(s) / Mentor(s)
Jun O. Liu, PhD
Cancer type
Blood
Research area
Drug Discovery
Award Program
Fellow